そもそもガンとは？| 免疫細胞療法とは| ガン免疫療法4つの特長| ガンの治療法|
●参考文献集
免疫療法
ガン臨床の現状把握のためのブックマーク(cancer information files) 免疫療法
ガンサポート情報センター どの治療法が優れているか、どのクリニックがよいか
●症例集
| Title | Author | Journal | Vol&Page | Year | Pub Med ID |
|---|---|---|---|---|---|
| 固層化CD3抗体により活性化したT Cell(CD3-LAK)を用いた養子免疫療法 | 関根暉彬 | Biotherapy | 4(10): 1606-1613 | 1990 | |
| Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies. | Kimoto Y, Tanaka T, Tanji Y, Fujiwara A, Taguchi T. |
Biotherapy. | 8(1):41-50. | 1994 | 7547080 |
| Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy. | Haruta I, Yamauchi K, Aruga A, Komatsu T, Takasaki K,
Hayashi N, Hanyu F. |
J Immunother Emphasis Tumor Immunol. | 19(3):218-23. | 1996 | 8811496 |
| Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results. | Tomita Y, Katagiri A, Saito K, Imai T, Saito T, Tanikawa T,
Terunuma M, Nishiyama T, Takahashi K. |
Int J Urol. | 5(1):16-21. | 1998 | 9535595 |
| Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels. | Ebina T, Ogama N, Shimanuki H, Kubota T, Isono N. | Cancer Immunol Immunother. | 52(9):555-60 | 2003 | 14627127 |
| A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. | Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Vetto JT, Seipp CA, Simpson C. | Surgery. | 100(2):262-72. | 1986 | 3526604 |
| A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. | Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al. | N Engl J Med. | 316(15):889-97. | 1987 | 3493432 |
| Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. | Steis RG, Urba WJ, VanderMolen LA, Bookman MA, Smith JW 2nd, Clark JW, Miller RL, Crum ED, Beckner SK, McKnight JE, et al. | J Clin Oncol. | 8(10):1618-29. | 1990 | 2213099 |
| Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. | Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH Jr, Benz LA, Fefer A. | J Clin Oncol. | 10(6):960-8. | 1992 | 1588376 |
| Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. | Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, et al. | J Natl Cancer Inst. | 85(8):622-32. | 1993 | 8468720 |
| Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report. | Takayama T, Makuuchi M, Sekine T, Terui S, Shiraiwa H, Kosuge T, Yamazaki S, Hasegawa H, Suzuki K, Yamagata M, et al. | Cancer. | 68(11):2391-6. | 1991 | 1657353 |
| Locoregional cellular immunotherapy for patients with advanced esophageal cancer. | Toh U, Yamana H, Sueyoshi S, Tanaka T, Niiya F, Katagiri K, Fujita H, Shirozou K, Itoh K. | Clin Cancer Res. | 6(12):4663-73 | 2000 | 11156218 |
| Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer. | Gomez GG, Hutchison RB, Kruse CA. | Cancer Treat Rev. | 27(6):375-402. | 2001 | 11908930 |
| A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. | Kimura H, Yamaguchi Y. | Cancer. | 80(1):42-9. | 1997 | 9210707 |
| Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. | Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. | Lancet. | 356(9232):802-7. | 2000 | 11022927 |
1. Morse M, et al. A phase 1 study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clinical Cancer Research. 1999, 5: 1331-1338.
2. Brossart P, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000, 96: 3102-3108.
3.?Triozzi PL, et al. Intratumoural injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer. 2000, 89 (12): 2646-2654.
4. Kobayashi T, et al. Regression of lymph node metastases by immunotherapy using autologous breast tumor-lysate pulsed dendritic cells: report of a case. Surg Today. 2001, 31: 513-516.
5. Pecher G. et al. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer immunol Immunother. 2002, 8(11-12): 669-73.
6. Dees CE, et al. Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. Cancer Immunol Immunother. 2004, 53: 777-785.
7.?Vonderheide RH, et al. Vaccination of cancer patients against telomerase induces functional antitumour CD8+ T Lymphocytes. Clinical Cancer Research. 2004, 10: 828-839.
8.?Avigan D, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Research. 2004, 10: 4699-4708.
9.?Svane IM, et al. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004, 53: 633-641.
10. Homma S, et al. Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12. Eur J Clin Invest. 2005, 35(4): 279-86.
11. Katano M, Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas. Anticancer Res. 2005, 25(6A): 3771-6.
12. Loveland BE, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma, Clin Cancer Res. 2006, 12(3): 869-877.
